Filing Flows › bioAffinity Technologies (BIAF) › Q3 2026 › vs Q2 2026
bioAffinity Technologies (BIAF) Q3 2026 vs Q2 2026 (quarter over quarter)
bioAffinity Technologies's revenue fell $440K (-29%) from $1.5M in Q2 2026 to $1.1M in Q3 2026. The biggest changes: Health Care, Patient Service −$381K (-31%); Histology Service Fees −$59K (-24%); Medical Director Fees −$337 (-2%).
bioAffinity Technologies, Q3 2026: revenue $1.1M (-26% year over year), operating margin -328.0%, net loss $5.3M, operating cash flow −$3.9M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Health Care, Patient Service | $863K | $1.2M | −$381K | -31% |
| Histology Service Fees | $190K | $248K | −$59K | -24% |
| Medical Director Fees | $17K | $18K | −$337 | -2% |
| Revenue | $1.1M | $1.5M | −$440K | -29% |
| Net loss | $5.3M | $3.4M | $1.9M | +57% |
| Costs & expenses | $6.3M | $4.9M | $1.5M | +30% |
| Operating costs | $4.6M | $4.8M | −$264K | -5% |
| Interest & other, net | $1.8M | $31K | $1.7M | 57× |
| Research & development | $389K | $362K | $28K | +8% |
| SG&A | $2.8M | $2.9M | −$99K | -3% |
| Other operating costs | $1.4M | $1.6M | −$193K | -12% |
| Operating cash sources | $5.3M | $3.4M | $1.9M | +57% |
| Depreciation & amortization | $67K | $62K | $5K | +9% |
| Share-based compensation | $139K | $785K | −$646K | -82% |
| Working capital & other | $1.2M | −$682K | $1.9M | — |
| Cash used in operations | $3.9M | $3.2M | $672K | +21% |
| Net loss absorbed | $5.3M | $3.4M | $1.9M | +57% |
Questions
How much did bioAffinity Technologies's revenue grow quarter over quarter in Q3 2026?
bioAffinity Technologies's revenue fell $440K (-29%) from $1.5M in Q2 2026 to $1.1M in Q3 2026.
What drove bioAffinity Technologies's revenue change in Q3 2026?
Health Care, Patient Service −$381K (-31%); Histology Service Fees −$59K (-24%); Medical Director Fees −$337 (-2%).